Link to the article in Clinical Cancer Research.] The study utilized Droplet's LymphDetect (TM) liquid biopsy assay for HPV-independent head & neck cancer. Results from two cohorts (initial n = 36, ...

Maina Modu, an immunization officer in Nigeria’s northeastern Borno state, lost his wife, Hauwa, to cervical cancer in 2011.

The Head and Neck Cancer Drugs/Therapeutics Market is experiencing substantial growth, valued at USD 4.2 Billion in 2024 and projected to reach USD 8.5 Billion by 2033. This expansion reflects ...

After decades of decline, rates of cervical cancer within Canada have plateaued, according to the Canadian Cancer Society — a ...

Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.

The oropharyngeal cancer market is anticipated to grow during the forecast period (2025--2034), driven by the launch of emerging therapies such as PDS Biotechnology's Versamune HPV, Inovio ...

PDS Biotechnology Corporation (NASDAQ: PDSB) Q3 2025 Earnings Call Transcript November 13, 2025 ...

A nanoparticle vaccine designed to fight cancers induced by human papillomavirus (HPV) eradicated tumors in an animal model ...

Get key insights from PDS Biotech’s Q3 2025 earnings call, including regulatory updates for PDS0101 in HPV16+ cancer and financial highlights.

Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced that Palmetto GBA, the Medicare Administrative Contractor that administers the Molecular ...

Preventable cancers drive rising toll Govind Sharma JAMMU, Nov 16: A new five-year cancer registry compiled at the Government ...

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck ...